Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
September 19 2023 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
its participation in the upcoming Cantor Global Healthcare
Conference 2023 being held in New York. Troy Wilson, Ph.D., J.D.,
President and Chief Executive Officer, is scheduled to participate
in a fireside chat at 10:55 a.m. ET / 7:55 a.m. PT on September 26,
2023.
A live audio webcast of the fireside chat will be available in
the investor section of Kura’s website at www.kuraoncology.com with
an archived replay available following the live event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways.
Ziftomenib is a once-daily, oral drug candidate targeting the
menin-KMT2A protein-protein interaction for the treatment of
genetically defined acute myeloid leukemia (AML) patients with high
unmet need. Kura is currently enrolling patients in a Phase 2
registration-directed trial of ziftomenib in NPM1-mutant relapsed
or refractory AML (KOMET-001). The Company is also conducting a
series of studies to evaluate ziftomenib in combination with
current standards of care, beginning with venetoclax/azacitidine
and standard induction cytarabine/daunorubicin chemotherapy in
NPM1-mutant and KMT2A-rearranged newly diagnosed and
relapsed/refractory AML (KOMET-007). Tipifarnib, a potent and
selective farnesyl transferase inhibitor (FTI), is currently in a
Phase 1/2 trial in combination with alpelisib for patients with
PIK3CA-dependent head and neck squamous cell carcinoma
(KURRENT-HN). Kura is also preparing to evaluate KO-2806, a
next-generation FTI, in a Phase 1 dose-escalation trial as a
monotherapy and in combination with other targeted therapies,
beginning with clear cell renal cell carcinoma (FIT-001). For
additional information, please visit Kura’s website at
www.kuraoncology.com and follow us on Twitter and LinkedIn.
Contacts
Investors:Pete De SpainExecutive Vice President, Investor
Relations &Corporate Communications(858)
500-8833pete@kuraoncology.com
Media:Alexandra WeingartenSenior Manager, Corporate
Communications(858) 500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024